Do you want to read an article? Please log in or register.
Vedolizumab for the treatment of Non-Inflammatory Bowel Disease Related Enteropathy
Inflammatory Bowel Disease
COMMENTED
Related content
Inflammatory Bowel Disease
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort
Eur J Gastroenterol Hepatol.
Godat S, Fournier N, Safroneeva E, Juillerat P, Nydegger A, Straumann A, Vavricka S, Biedermann L, Greuter T, Fraga M, Abdelrahman K, Hahnloser D, Sauter B, Rogler G, Michetti P, Schoepfer AM, Swiss IBD Cohort Study Group
doi: 10.1097/MEG.
Inflammatory Bowel Disease
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice
Biologicals.
Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T
doi: 10.1016/j.biologicals.
Inflammatory Bowel Disease
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review
J Crohns Colitis.
Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L
doi: 10.1093/ecco-jcc/jjz095.
Inflammatory Bowel Disease
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease
United European Gastroenterol J.
Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A
doi: 10.1177/2050640619873784.
RECOMMENDED
Inflammatory Bowel Disease
Predicting, Preventing, and Managing Treatment-related Complications in Patients With Inflammatory Bowel Diseases
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol.
Beaugerie L, Rahier JF, Kirchgesner J
doi: 10.1016/j.cgh.2020.02.009.
Inflammatory Bowel Disease
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Aliment Pharmacol Ther.
Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group
doi: 10.1111/apt.14930.
Inflammatory Bowel Disease
Treatment of Inflammatory Bowel Disease in the Older Patient
Inflamm Bowel Dis.
Dorreen A, Heisler C, Jones J
doi: 10.1093/ibd/izy023.
Inflammatory Bowel Disease
Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study
Therap Adv Gastroenterol.
Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M
doi: 10.1177/1756284819895217.
Inflammatory Bowel Disease
A product review of vedolizumab in inflammatory bowel disease
Hum Vaccin Immunother.
Battat R, Dulai PS, Jairath V, Vande Casteele N
doi: 10.1080/21645515.